...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: New Apabetalone Fabry Disease Publication

RVX management is fearful their drug fails on one or more indications in the first round and really have no desire to push a timeline hard,,,,,the team is handsomely rewarded for the bulk of time over the span of a year ,,most of which is clearly inaction. 3rd parties know more about the MOA of apabetalone than does the team,,,its so obvious it hurts. Jmo.

Share
New Message
Please login to post a reply